A sucrose synthase and its application in biosynthesis of steviol glycosides

Through the combined use of improved sucrose synthase and its mutants with glucosyltransferase, the problems of low catalytic efficiency and poor stability of sucrose synthase in the prior art have been solved, and the efficient preparation of steviol glycosides is achieved, suitable for industrial production, and reduced production costs.

CN118755690BActive Publication Date: 2024-11-19SICHUAN INGIA BIOSYNTHETIC CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411245571.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-19
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

In the prior art, the catalytic efficiency of sucrose synthesizer is limited, which affects the synthesis efficiency of biosynthetic steviol glycosides. The enzyme is poor in stability and is difficult to maintain activity under strict operating conditions, which increases the cost and complexity of industrial production. .

Method used

It provides an improved sucrose synthase and its mutant with high catalytic efficiency and stability. Through specific amino acid sequence variation and nucleotide sequence design, combined with the combined use of glucosyltransferase, the efficient preparation of steviol glycosides is achieved. cascade reaction.

Benefits of technology

It improves the conversion and yield of steviol glycoside, reduces the occurrence of side reactions, ensures the purity and quality of the product, is suitable for industrial production, and reduces production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to the field of biotechnology, and in particular to a sucrose synthase and its application in the biosynthesis of steviol glycosides. TgSUS , its mutants and their applications. The sucrose synthase and its mutants of the present invention have high catalytic efficiency. When used in combination with glucosyltransferase, they can be used to efficiently prepare stevioside (rebaudioside A, rebaudioside D or rebaudioside M), realize cascade reaction, provide options for optimizing process conditions for further large-scale industrial production, and are more conducive to large-scale industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a sucrose synthase and application thereof in biosynthesis of steviol glycosides. Background Art

[0002] Sucrose synthase is a key enzyme that catalyzes sucrose synthesis in plants. It catalyzes the formation of sucrose from uridine diphosphate glucose (UDPG) and fructose. It is an important component of sugar synthesis and transportation during plant photosynthesis and plays a vital role in plant growth and development and sugar distribution. Sucrose synthase not only plays its traditional role in plants, but is also used in the field of biosynthesis. It is used in microbial systems to enhance metabolic pathways and produce high value-added carbohydrate products. For example, by heterologously expressing sucrose synthase in Escherichia coli or yeast, glucose and fructose can be effectively converted into sucrose, which can then be used as a precursor for the synthesis of other complex sugars or glycosides. This approach provides a new strategy for the production of specific types of glycosides, such as steviol glycosides, which helps meet the needs of specific sweetener markets and provides new tools and approaches for synthetic biology.

[0003] Stevioside is a series of natural sweeteners extracted from Stevia rebaudiana, including rebaudioside M (Reb M), rebaudioside D (Reb D), rebaudioside A (Reb A), etc. Stevioside is regarded as a healthy alternative to traditional sweeteners due to its high sweetness and calorie-free characteristics. Biosynthesis of steviol glycoside provides a safe, healthy and environmentally friendly production method. In the biosynthesis of steviol glycoside, sucrose synthase first synthesizes the necessary sugar precursors to provide substrates for glucosyltransferase, and then glucosyltransferase transfers the sugar group of sucrose or other sugars to specific receptor molecules to form sweet glycosides. The combined use of sucrose synthase and glucosyltransferase can improve the synthesis efficiency of steviol glycoside.

[0004] The synthesis efficiency of biosynthetic steviol glycosides is a research focus in this field. Although the combined use of sucrose synthase and glucosyltransferase has achieved certain results, there is still room for improvement. The catalytic efficiency of sucrose synthase is affected by many factors, including temperature, pH value, substrate concentration, enzyme concentration, etc. For example, too high or too low temperature may cause enzyme inactivation, and extreme pH values ​​may destroy the active site or overall structure of the enzyme. Therefore, it is particularly important to improve the stability of sucrose synthase. Good stability can not only expand the application range of the enzyme and keep it active under more stringent operating conditions, but also reduce the degradation of the enzyme in the industrial production process, reduce costs, and improve production efficiency. Summary of the invention

[0005] In view of this, the present invention provides a sucrose synthase and its application in the biosynthesis of steviol glycosides. The series of sucrose synthases provided by the present invention solve the technical problem of limited catalytic efficiency of sucrose synthase in the prior art. The sucrose synthase of the present invention has high catalytic efficiency. When used in combination with glucosyltransferase, it can be used to efficiently prepare steviol glycosides (rebaudioside A, rebaudioside D or rebaudioside M), realize cascade reaction, provide a choice of process condition optimization for further realizing large-scale industrial production, and is more conducive to realizing large-scale industrial production.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a sucrose synthase having:

[0008] (1) the amino acid sequence shown in SEQ ID NO: 1; or

[0009] (2) An amino acid sequence obtained by substituting, deleting or adding one or more residues of the amino acid sequence shown in (1), and having the same or similar function as (1); or

[0010] (3) An amino acid sequence that is at least 90% homologous to the amino acid sequence shown in (1) or (2).

[0011] The present invention also provides a nucleic acid molecule having a nucleotide sequence encoding the sucrose synthase.

[0012] In some specific embodiments of the present invention, the nucleotide sequence of the above nucleic acid molecule comprises:

[0013] (1) the nucleotide sequence shown in SEQ ID NO: 2; or

[0014] (2) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as (1); or

[0015] (3) A nucleotide sequence having at least 90% homology with the nucleotide sequence shown in (1) or (2).

[0016] The present invention also provides a mutant of the above-mentioned sucrose synthase, wherein the mutation site is at least one of V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, F676Y, and N776Y.

[0017] In some specific embodiments of the present invention, the mutation site of the mutant is any one of V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, F676Y, and N776Y.

[0018] In some specific embodiments of the present invention, the mutation site of the mutant is any one of the following:

[0019] V158S and F170G; or

[0020] F170G and K443R; or

[0021] F170G and N653D; or

[0022] V158S and F676Y; or

[0023] K443R and F676Y; or

[0024] G302S and K443R; or

[0025] V158S, F170G and K443R; or

[0026] F170G, K443R, F676Y; or

[0027] V158S, F170G, K443R, E674K and F676Y; or

[0028] V158S, F170G, K443R, E674K, F676Y and N776Y; or

[0029] G301A, G302S, K443R, Q647E, N653D, and F676Y; or

[0030] V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, and F676Y; or

[0031] V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, F676Y, and N776Y.

[0032] The present invention also provides a nucleic acid molecule having a nucleotide sequence encoding the mutant.

[0033] In some specific embodiments of the present invention, the nucleotide sequence encoding the mutant in the nucleic acid molecule includes any one of the following:

[0034] V158S: SEQ ID NO: 2 in which GTG at positions 472 to 474 is replaced by TCC; or

[0035] F170G: SEQ ID NO: 2 wherein TTC at positions 508 to 510 is replaced by GGC; or

[0036] G301A: SEQ ID NO: 2 wherein GGT at positions 901 to 903 is replaced by GCT; or

[0037] G302S: SEQ ID NO: 2 in which positions 904 to 906 of GGT are replaced by TCT; or

[0038] K443R: SEQ ID NO: 2, wherein AAG at positions 1327-1329 is replaced by CGT; or

[0039] Q647E: SEQ ID NO: 2 wherein CAG at positions 1939-1941 is substituted with GAA; or

[0040] N653D: SEQ ID NO: 2 wherein AAC at positions 1957 to 1959 are replaced by GAC; or

[0041] E674K: SEQ ID NO: 2, wherein GAA at position 2020-2022 is replaced by AAG; or

[0042] F676Y: SEQ ID NO: 2 wherein TTC at positions 2026-2028 is replaced by TAC; or

[0043] N776Y: SEQ ID NO: 2, wherein AAC at positions 2326 to 2328 is replaced by TAC; or

[0044] V158S and F170G: SEQ ID NO: 2, wherein GTG at positions 472-474 is replaced by TCC, and TTC at positions 508-510 is replaced by GGC; or

[0045] F170G and K443R: SEQ ID NO: 2, wherein TTC at positions 508-510 is replaced by GGC, and AAG at positions 1327-1329 is replaced by CGT; or

[0046] F170G and N653D: SEQ ID NO: 2, wherein TTC at positions 508-510 is replaced by GGC, and AAC at positions 1957-1959 is replaced by GAC; or

[0047] V158S and F676Y: SEQ ID NO: 2, in which GTG at positions 472-474 is replaced by TCC, and TTC at positions 2026-2028 is replaced by TAC; or

[0048] K443R and F676Y: SEQ ID NO: 2, wherein AAG at positions 1327-1329 are replaced by CGT, and TTC at positions 2026-2028 are replaced by TAC; or

[0049] G302S and K443R: SEQ ID NO: 2, in which GGT at positions 904-906 is replaced by TCT, and AAG at positions 1327-1329 is replaced by CGT; or

[0050] V158S, F170G and K443R: SEQ ID NO: 2, wherein GTG at positions 472-474 is replaced by TCC, TTC at positions 508-510 is replaced by GGC, and AAG at positions 1327-1329 is replaced by CGT; or

[0051] F170G, K443R, F676Y: SEQ ID NO: 2, wherein TTC at positions 508-510 is replaced by GGC, AAG at positions 1327-1329 is replaced by CGT, and TTC at positions 2026-2028 is replaced by TAC; or

[0052] V158S, F170G, K443R, E674K and F676Y: SEQ ID NO: 2 in which GTG at positions 472-474 is replaced by TCC, TTC at positions 508-510 is replaced by GGC, AAG at positions 1327-1329 is replaced by CGT, GAA at positions 2020-2022 is replaced by AAG, and TTC at positions 2026-2028 is replaced by TAC; or

[0053] V158S, F170G, K443R, E674K, F676Y and N776Y: SEQ ID NO: 2 wherein GTG at positions 472-474 is replaced by TCC, TTC at positions 508-510 is replaced by GGC, AAG at positions 1327-1329 is replaced by CGT, GAA at positions 2020-2022 is replaced by AAG, TTC at positions 2026-2028 is replaced by TAC, and AAC at positions 2326-2328 is replaced by TAC; or

[0054] G301A, G302S, K443R, Q647E, N653D and F676Y: SEQ ID NO: 2 wherein GGT at positions 901-903 is replaced by GCT, GGT at positions 904-906 is replaced by TCT, AAG at positions 1327-1329 is replaced by CGT, CAG at positions 1939-1941 is replaced by GAA, AAC at positions 1957-1959 is replaced by GAC, and TTC at positions 2026-2028 is replaced by TAC; or

[0055] V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K and F676Y: SEQ ID NO: 2 wherein GTG at positions 472-474 is replaced by TCC, TTC at positions 508-510 is replaced by GGC, GGT at positions 901-903 is replaced by GCT, GGT at positions 904-906 is replaced by TCT, AAG at positions 1327-1329 is replaced by CGT, CAG at positions 1939-1941 is replaced by GAA, AAC at positions 1957-1959 is replaced by GAC, GAA at positions 2020-2022 is replaced by AAG, and TTC at positions 2026-2028 is replaced by TAC; or

[0056] V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, F676Y and N776Y: SEQ ID NO: 2 in which GTG at position 472-474 is replaced by TCC, TTC at position 508-510 is replaced by GGC, GGT at position 901-903 is replaced by GCT, GGT at position 904-906 is replaced by TCT, AAG at position 1327-1329 is replaced by CGT, CAG at position 1939-1941 is replaced by GAA, AAC at position 1957-1959 is replaced by GAC, GAA at position 2020-2022 is replaced by AAG, TTC at position 2026-2028 is replaced by TAC, and AAC at position 2326-2328 is replaced by TAC.

[0057] The present invention also provides an expression vector having any of the following:

[0058] (a1), a nucleic acid molecule having a nucleotide sequence encoding the above-mentioned sucrose synthase;

[0059] (a2) A nucleic acid molecule having a nucleotide sequence encoding the above mutant.

[0060] In some specific embodiments of the present invention, the backbone of the above expression vector is pETDuet-1.

[0061] The present invention also provides an expression vector combination, comprising the above expression vector, and further comprising:

[0062] An expression vector having a genetic element for expressing UGT76G1; or

[0063] An expression vector having a genetic element for expressing EUGT11; or

[0064] Contains expression vectors for expressing UGT76G1 and EUGT11.

[0065] In some specific embodiments of the present invention, the backbone of the expression vector having the gene element for expressing UGT76G1 in the above-mentioned expression vector combination is pRSFDuet-1.

[0066] In some specific embodiments of the present invention, the backbone of the expression vector having the gene element for expressing EUGT11 in the above-mentioned expression vector combination is pRSFDuet-1.

[0067] In some specific embodiments of the present invention, the backbone of the expression vector for expressing UGT76G1 and EUGT11 in the above-mentioned expression vector combination is pRSFDuet-1.

[0068] The present invention also provides a host cell having any of the following:

[0069] (b1), a nucleic acid molecule having a nucleotide sequence encoding the above-mentioned sucrose synthase;

[0070] (b2), a nucleic acid molecule having a nucleotide sequence encoding the mutant;

[0071] (b3), the above-mentioned expression vector;

[0072] (b4), the above expression vector combination;

[0073] The host cell includes bacteria;

[0074] The bacteria include Escherichia coli.

[0075] The present invention also provides a method for preparing sucrose synthase, which is prepared based on any of the following:

[0076] (c1), a nucleic acid molecule having a nucleotide sequence encoding the above-mentioned sucrose synthase;

[0077] (c2) a nucleic acid molecule having a nucleotide sequence encoding the mutant;

[0078] (c3), the above-mentioned expression vector;

[0079] (c4), the above expression vector combination;

[0080] (c5) the above-mentioned host cell.

[0081] The present invention also provides the use of any of the following in the preparation of steviol glycosides:

[0082] (d1), the above-mentioned sucrose synthase;

[0083] (d2), the above mutants;

[0084] (d3), sucrose synthase prepared according to the above preparation method;

[0085] The steviol glycoside includes at least one of Reb A, Reb D and Reb M.

[0086] The present invention also provides a method for preparing steviol glycoside, comprising: preparing steviol glycoside based on the above host cell;

[0087] The reaction system prepared comprises:

[0088] 0.1 g / mL, 0.15 g / mL, 0.2 g / mL, 0.25 g / mL or 0.3 g / mL of the above host cells;

[0089] 55 mM, 56 mM, 57 mM, 58 mM, 59 mM, 60 mM, 61 mM, 62 mM, 63 mM, 64 mM, or 65 mM trisodium citrate;

[0090] 95 mM, 96 mM, 97 mM, 98 mM, 99 mM, 100 mM, 101 mM, 102 mM, 103 mM, 104 mM or 105 mM sodium phosphate buffer at pH 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5;

[0091] 0.05mM, 0.06mM, 0.07mM, 0.08mM, 0.09mM, 0.1mM, 0.11mM, 0.12mM, 0.13mM, 0.14mM or 0.15mM MgCl 2 ;

[0092] 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5% (v / v) xylene;

[0093] 350 g / L, 360 g / L, 370 g / L, 380 g / L, 390 g / L, 400 g / L, 410 g / L, 420 g / L, 430 g / L, 440 g / L or 450 g / L sucrose;

[0094] 55 g / L, 56 g / L, 57 g / L, 58 g / L, 59 g / L, 60 g / L, 61 g / L, 62 g / L, 63 g / L, 64 g / L or 65 g / L substrate;

[0095] The temperature of the conversion is 38°C, 39°C, 40°C, 41°C or 42°C;

[0096] The conversion time is 12 h, 18 h, 24 h, 30 h, 36 h, 48 h, 54 h, 60 h, 66 h or 72 h;

[0097] The substrate comprises Reb A or Reb D;

[0098] The steviol glycoside includes at least one of Reb A, Reb D and Reb M.

[0099] The sucrose synthase of the present invention and its mutation-optimized variants have the following effects:

[0100] The present invention uses sucrose synthase and its variants after mutation optimization in combination with glucosyltransferase, which can be used to efficiently prepare rebaudioside A, rebaudioside D and rebaudioside M to achieve a cascade reaction. The sucrose synthase and its mutants in the process of catalyzing the synthesis of steviol glycosides not only improve the conversion rate and yield of the reaction, but also reduce the occurrence of side reactions, thereby ensuring the purity and quality of the product. In addition, the sucrose synthase of the present invention can maintain high catalytic efficiency and has significant advantages in industrial production. DETAILED DESCRIPTION

[0101] The present invention discloses a sucrose synthase and its application in the biosynthesis of steviol glycosides. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0102] The present application provides a sucrose synthase TgSUS, sourced from tulip (Tulipa gesneriana), the amino acid sequence of the sucrose synthase TgSUS is shown in SEQ ID NO: 1;

[0103] The codon-optimized nucleic acid sequence of E. coli is shown in SEQ ID NO:2.

[0104] The present application also provides a mutant of the above-mentioned sucrose synthase TgSUS, wherein the mutation sites include at least one of V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, F676Y, and N776Y. The above mutation sites also include multiple mutations: V158S / F170G, F170G / K443R, F170G / N653D, V158S / F676Y, K443R / F676Y, G302S / K443R, V158S / F170G / K443R, F170G / K443R / F676Y, V158S / F170G / K443R / E674K / F676Y, V158S / F170G / K443R / E674K / F676Y / N776Y、G301A / G302S / K443R / Q647E / N653D / F676Y、V158S / F170G / G301A / G302S / K443R / Q647E / N653D / E674K / F676Y, V158S / F170G / G301A / G302S / K443R / Q647E / N653D / E674K / F676Y / N776Y.

[0105] The sequence information involved in this application is as follows:

[0106] TgSUS is derived from Tulipa gesneriana, amino acid (protein) sequence SEQ ID NO: 1:

[0107] MADRAMTRVHSVRERLTDTLSAHKNELLALFSRFVKQGQGMLQPHQLLTEYEAVIPAADREKLKDGVFEDVLKAAQEAIVIPPWVALAIRPRPGVWEYVRVNVSELAVEELTVPEYLQFKEELVDGSGQSNFTLELDFEPFNASFPRPSLSKSIGNGVQFLNRHLSSKLFHDKESMYPLLNFLKEHHYNGTSMMLNDRIQTLGALQASLRRADEYVLSLPLDTPYSDFGHRFQELGLEKGWGDNAKRVHENLHLLLDLLEAPDPCTLENFLGTIPMVFNVVILSPHGYFAQANVLGYPDTGGQVVYILDQVRAMESEMLLRIKQQGLDITPRILIVTRLLPDAVGTTCGQRLEKVLGTEHTHILRVPFRTEHGILRKWISRFEVWPYLETYAEDVANEVAGELQATPDLIIGNYSDGNLVASLMAHKLGVTQCTIAHALEKTKYPNSDLYWKKFEKQYHFSCQFTADLIAMNHADFIITSTFQEIAGSKDTVGQYESHTGFTLPGLYRVVHGIDVFDPKFNIVSPGADMSIYFPYTEAEKRLTALHPEIEELLYSSAESTEYKFGLKDKTKPIIFSMARLDRVKNMTGLVELYAKNDRLKELVNLVVVCGDHAKASKDLEEQAELKKMYSLIEEYKLDGHIRWISAQMNRVRNGELYRYIADSKGVFVQPAFYEAFGLTVVESMTCGLPTFATCHGGPAEIIVHGVSGYHIDPYHGDKAAELLVDFFEKSKKDQTHWDAISNGGLKRIYEKYTWKIYSERLLTLAGVYGFWKYVSNLDRRETKRYLEMFYALKYRNLAKSVPLAVDGEAAVNGKICTLGC;

[0108] Escherichia coli codon-optimized nucleic acid sequence SEQ ID NO: 2:

[0109]

[0110] The primer sequence information involved in this application is shown in Table 1.

[0111] Table 1: Primer design

[0112]

[0113] EUGT11 is derived from rice ( Oryza sativa Japonica Group ), and the amino acid (protein) sequence accession number is GenBank: AAS07253;

[0114] E. coli codon-optimized nucleic acid sequence SEQ ID NO: 39:

[0115]

[0116] UGT76G1 is derived from Stevia rebaudiana, and the amino acid (protein) sequence accession number is GenBank: QTI50358;

[0117] E. coli codon-optimized nucleic acid sequence SEQ ID NO: 40:

[0118]

[0119] AtSUS1 nucleic acid sequence, derived from Arabidopsis thaliana, amino acid (protein) sequence accession number is GenBank: QKZ93247;

[0120] E. coli codon-optimized nucleic acid sequence SEQ ID NO: 41:

[0121]

[0122] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.

[0123] The present invention will be further described below in conjunction with the embodiments.

[0124] Example 1

[0125] 1. Cloning of glycosyltransferase and sucrose synthase genes

[0126] TgSUS, EUGT11, UGT76G1, and AtSUS1 were codon-optimized for Escherichia coli, and full-length DNA sequences were synthesized.

[0127] 2. Construction of recombinant expression vector

[0128] Using pETDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone TgSUS and the linearized pETDuet-1 vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Amp-resistant plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL LB medium containing Amp for sequencing verification. The recombinant plasmid pETDuet-1-TgSUS with correct sequencing was extracted.

[0129] Using pRSFDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone UGT76G1 and the linearized pRSFDuet-1 vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Kan resistance plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL LB medium containing Kan for sequencing verification. The recombinant plasmid pRSFDuet-1-UGT76G1 with correct sequencing was extracted.

[0130] Using pRSFDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone EUGT11 and the linearized pRSFDuet-1 vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Kan resistance plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL LB medium containing Kan for sequencing verification. The recombinant plasmid pRSFDuet-1-EUGT11 with correct sequencing was extracted.

[0131] The same strategy as above was adopted to construct a recombinant expression plasmid using the In-Fusion method. PCR amplification primers containing homology arms were designed (see Table 1) to clone EUGT11 and the linearized pRSFDuet-1-UGT76G1 recombinant vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were homologously recombined. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Kan-resistant plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL of LB medium containing Kan for sequencing verification. The recombinant plasmid pRSFDuet-1-UGT76G1-EUGT11 with correct sequencing was extracted.

[0132] Using pETDuet-1 as the expression vector, the In-Fusion strategy was used to construct a recombinant expression plasmid. PCR amplification primers containing homology arms were designed (see Table 1) to clone AtSUS1 and the linearized pETDuet-1 recombinant vector. According to the instructions of the kit, the DNA fragment and the linearized vector fragment were subjected to homologous recombination reaction. After reacting at 50 degrees for 1 hour, the competent cells of E. coli DH5α were transformed and coated with Amp-resistant plates and cultured overnight at 37 degrees. Positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL LB medium containing Amp for sequencing verification. The recombinant plasmid pETDuet-1-AtSUS1 (control example) with correct sequencing was extracted.

[0133] 3. TgSUS mutant construction method: plasmid loop p mutation.

[0134] Take the V158S single point mutation as an example:

[0135] Using pETDuet-1-TgSUS as a template, mutant primers were designed (sequences are shown in Table 1) for PCR amplification. The PCR product was digested with restriction endonuclease DpnI for 2 h to remove the template. The target band was recovered after agarose gel electrophoresis and ddH 2O was used for elution, and then transformed into E. coli DH5α competent cells, coated with Amp-resistant plates and cultured at 37°C overnight; positive clones were screened by colony PCR, and positive clones were picked and placed in 5 mL of LB medium containing Amp for sequencing verification, and the correct plasmid pETDuet-1-TgSUS (V158S) was extracted.

[0136] The remaining plasmid construction methods were the same as those for the V158S single point mutation, and the primers were shown in Table 1. The plasmids obtained were as follows:

[0137] pETDuet-1-TgSUS (F170G);

[0138] pETDuet-1-TgSUS (G301A);

[0139] pETDuet-1-TgSUS (G302S);

[0140] pETDuet-1-TgSUS (K443R);

[0141] pETDuet-1-TgSUS (Q647E);

[0142] pETDuet-1-TgSUS (N653D);

[0143] pETDuet-1-TgSUS (E674K);

[0144] pETDuet-1-TgSUS (F676Y);

[0145] pETDuet-1-TgSUS (N776Y);

[0146] pETDuet-1-TgSUS (V158S / F170G);

[0147] pETDuet-1-TgSUS (F170G / K443R);

[0148] pETDuet-1-TgSUS (F170G / N653D);

[0149] pETDuet-1-TgSUS (V158S / F676Y);

[0150] pETDuet-1-TgSUS (K443R / F676Y);

[0151] pETDuet-1-TgSUS (G302S / K443R);

[0152] pETDuet-1-TgSUS (V158S / F170G / K443R);

[0153] pETDuet-1-TgSUS (F170G / K443R / F676Y);

[0154] pETDuet-1-TgSUS (V158S / F170G / K443R / E674K / F676Y);

[0155] pETDuet-1-TgSUS (V158S / F170G / K443R / E674K / F676Y / N776Y);

[0156] pETDuet-1-TgSUS (G301A / G302S / K443R / Q647E / N653D / F676Y);

[0157] pETDuet-1-TgSUS (V158S / F170G / G301A / G302S / K443R / Q647E / N653D / E674K / F676Y);

[0158] pETDuet-1-TgSUS (V158S / F170G / G301A / G302S / K443R / Q647E / N653D / E674K / F676Y / N776Y).

[0159] 4. Construction of Reb A-producing recombinant expression bacteria

[0160] (1) Construction of recombinant expression strains Ste-RA01 to Ste-RA24

[0161] The recombinant plasmids pETDuet-1-TgSUS and pRSFDuet-1-UGT76G1 were co-transformed into E. coli BL21 (DE3) to obtain the recombinant strain, which was frozen in a -80°C refrigerator for future use.

[0162] The frozen recombinant strain was inoculated into 5-10 mL of LB medium containing Amp and Kan resistance, and cultured at 37°C overnight to prepare seed solution; the seed solution was inoculated into 50 mL of TB medium at a 1% inoculum, and cultured at 200 rpm at 37°C until OD 600 When the p value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the bacteria were collected by centrifugation at 12,000 rpm and 4℃ to obtain the recombinant expression bacteria Ste-RA01, which were stored at -20℃ for future use.

[0163] The construction and preparation methods of the other recombinant expression bacteria containing TgSUS mutants were the same as Ste-RA01, and recombinant expression bacteria Ste-RA02 to Ste-RA24 were obtained respectively.

[0164] (2) Construction of control bacteria Ste-RA00

[0165] The recombinant plasmids pETDuet-1-AtSUS1 and pRSFDuet-1-UGT76G1 were co-transformed into E. coli BL21 (DE3), and then the recombinant expression bacteria Ste-RA00 were obtained using the same protocol as above and stored at -20°C for future use.

[0166] Table 2: Recombinant expression bacteria Ste-RA00 to Ste-RA24 and expression plasmids

[0167]

[0168] 5. Construction of Reb D-producing recombinant expression bacteria

[0169] (1) Construction of recombinant expression strains Ste-RD01 to Ste-RD24

[0170] The recombinant plasmids pETDuet-1-TgSUS and pRSFDuet-1-EUGT11 were co-transformed into E. coli BL21 (DE3) to obtain the recombinant strain, which was frozen in a -80°C refrigerator for future use.

[0171] The frozen recombinant strain was inoculated into 5-10 mL of LB medium containing Amp and Kan resistance, and cultured at 37°C overnight to prepare seed solution; the seed solution was inoculated into 50 mL of TB medium at a 1% inoculum, and cultured at 200 rpm at 37°C until OD 600 When the p value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the bacteria were collected by centrifugation at 12,000 rpm and 4℃ to obtain the recombinant expression bacteria Ste-RD01, which were stored at -20℃ for future use.

[0172] The construction and preparation methods of the other recombinant expression bacteria containing TgSUS mutants were the same as Ste-RD01, and recombinant expression bacteria Ste-RD01 to Ste-RD24 were obtained respectively.

[0173] (2) Construction of control bacteria Ste-RD00

[0174] The recombinant plasmids pETDuet-1-AtSUS1 and pRSFDuet-1-EUGT11 were co-transformed into E. coli BL21 (DE3), and then the recombinant expression bacteria Ste-RD00 were obtained using the same protocol as above and stored at -20°C for future use.

[0175] Table 3: Recombinant expression bacteria Ste-RD00 to Ste-RD24 and expression plasmids

[0176]

[0177] 6. Construction of Reb M-producing recombinant expression bacteria

[0178] (1) Construction of recombinant expression strains Ste-RM01 to Ste-RM24

[0179] The recombinant plasmids pETDuet-1-TgSUS and pRSFDuet-1-UGT76G1-EUGT11 were co-transformed into E. coli BL21 (DE3) to obtain the recombinant strain, which was frozen in a -80°C refrigerator for future use.

[0180] The frozen recombinant strain was inoculated into 5-10 mL of LB medium containing Amp and Kan resistance, and cultured at 37°C overnight to prepare seed solution; the seed solution was inoculated into 50 mL of TB medium at a 1% inoculum, and cultured at 200 rpm at 37°C until OD 600 When the p value reached 0.6-0.8, 0.1 mM IPTG was added and the expression was induced at 22℃ for 24 h. Then, the bacteria were collected by centrifugation at 12,000 rpm and 4℃ to obtain the recombinant expression bacteria Ste-RM01, which were stored at -20℃ for future use.

[0181] The construction and preparation methods of the other recombinant expression bacteria containing TgSUS mutants were the same as Ste-RM01, and recombinant expression bacteria Ste-RM01 to Ste-RM24 were obtained respectively.

[0182] (2) Construction of control bacteria Ste-RM00

[0183] The recombinant plasmids pETDuet-1-AtSUS1 and pRSFDuet-1-UGT76G1-EUGT11 were co-transformed into E. coli BL21 (DE3), and then the recombinant expression bacteria Ste-RM00 were obtained using the same protocol as above and stored at -20°C for future use.

[0184] Table 4: Recombinant expression bacteria Ste-RM00 to Ste-RM24 and expression plasmids

[0185]

[0186] Example 2: Whole-cell biotransformation reaction experimental verification

[0187] 1. Experimental verification of biotransformation reaction of recombinant bacteria producing Reb A

[0188] The recombinant expression cells Ste-RA00 to Ste-RA24 obtained in Example 1 were resuspended and washed twice with 100 mM sodium phosphate buffer at pH 8.0 to obtain wet cells, which were used for whole-cell catalytic reaction to verify the conversion rate.

[0189] The biotransformation reaction system is:

[0190] 0.2 g / mL wet bacteria, 60 mM trisodium citrate, 100 mM sodium phosphate buffer pH 8.0, 0.1 mM MgCl 2 , 1% (v / v) xylene, 400 g / L sucrose and 60 g / L stevioside (Stv) substrate, the reaction temperature was 40°C, and the reaction time was 24 h. After the reaction was completed, an equal volume of methanol was added to quench, and the precipitate was removed by centrifugation at 12,000 rpm for 10 min. The supernatant was filtered through a 0.22 μm filter membrane and used for HPLC analysis.

[0191] The HPLC detection conditions were: isocratic 33% acetonitrile-67% phosphoric acid water (pH 3.0), detection wavelength of 210 nm, and column temperature of 40°C. The contents of stevioside and Reb A in the reaction samples were determined, and the conversion rate of Reb A was calculated. The detection results are shown in Table 5.

[0192] Table 5: Biotransformation reaction data of recombinant expression bacteria producing Reb A

[0193]

[0194] 2. Experimental verification of biotransformation reaction of recombinant bacteria producing Reb D

[0195] The recombinant expression cells Ste-RD00 to Ste-RD24 obtained in Example 1 were resuspended and washed twice with 100 mM sodium phosphate buffer at pH 8.0 to obtain wet cells, which were used for whole-cell catalytic reaction to verify the conversion rate.

[0196] The biotransformation reaction system is:

[0197] 0.2 g / mL wet bacteria, 60 mM trisodium citrate, 100 mM sodium phosphate buffer pH 8.0, 0.1 mM MgCl 2 , 1% (v / v) xylene, 400 g / L sucrose and 60 g / L rebaudioside A (Reb A), the reaction temperature was 40°C, and the reaction time was 24 h. After the reaction was completed, an equal volume of methanol was added to quench, and the precipitate was removed by centrifugation at 12,000 rpm for 10 min. The supernatant was filtered through a 0.22 μm filter membrane and used for HPLC analysis.

[0198] The HPLC detection conditions were: isocratic 33% acetonitrile-67% phosphoric acid water (pH 3.0), detection wavelength of 210 nm, and column temperature of 40°C. The contents of Reb D and Reb A in the reaction samples were determined, and the conversion rate of Reb D was calculated. The detection results are shown in Table 6.

[0199] Table 6: Biotransformation reaction data of recombinant expression bacteria producing Reb D

[0200]

[0201] 3. Experimental verification of biotransformation reaction of recombinant bacteria producing Reb M

[0202] The recombinant expression cells Ste-RM00 to Ste-RM24 obtained in Example 1 were resuspended and washed twice with 100 mM sodium phosphate buffer at pH 8.0 to obtain wet cells, which were used for whole-cell catalytic reaction to verify the conversion rate.

[0203] The biotransformation reaction system is:

[0204] 0.2 g / mL wet bacteria, 60 mM trisodium citrate, 100 mM sodium phosphate buffer pH 8.0, 0.1 mM MgCl 2 , 1% (v / v) xylene, 400 g / L sucrose and 60 g / L rebaudioside A (Reb A) substrate, the reaction temperature was 40°C, and the reaction time was 24 h. After the reaction was completed, an equal volume of methanol was added to quench, and the precipitate was removed by centrifugation at 12,000 rpm for 10 min. The supernatant was filtered through a 0.22 μm filter membrane and used for HPLC analysis.

[0205] The HPLC detection conditions were: isocratic 33% acetonitrile-67% phosphoric acid water (pH 3.0), detection wavelength of 210 nm, and column temperature of 40°C. The contents of Reb A, Reb D, and Reb M in the reaction samples were determined, and the conversion rate of Reb M was calculated. The detection results are shown in Table 7.

[0206] Table 7: Biotransformation reaction data of recombinant expression bacteria producing Reb M

[0207]

[0208] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A mutant of sucrose synthase, the sequence of which is shown in SEQ ID NO: 1, characterized in that: The mutation sites are: V158S; or F170G; or G301A; or G302S; or K443R; or Q647E; or N653D; or E674K; or F676Y; or N776Y; or V158S and F170G; or F170G and K443R; or F170G and N653D; or V158S and F676Y; or K443R and F676Y; or G302S and K443R; or V158S, F170G and K443R; or F170G, K443R, F676Y; or V158S, F170G, K443R, E674K and F676Y; or V158S, F170G, K443R, E674K, F676Y and N776Y; or G301A, G302S, K443R, Q647E, N653D, and F676Y; or V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, and F676Y; or V158S, F170G, G301A, G302S, K443R, Q647E, N653D, E674K, F676Y, and N776Y.

2. A nucleic acid molecule, characterized in that The sequence is a nucleotide sequence encoding the mutant according to claim 1.

3. An expression vector, characterized in that A nucleic acid molecule according to claim 2.

4. A host cell, excluding a totipotent cell, characterized in that Have any of the following: (b1), the nucleic acid molecule according to claim 2; (b2) The expression vector according to claim 3.

5. A method for preparing sucrose synthase, characterized in that: Prepared based on any of the following: (c1), the nucleic acid molecule according to claim 2; (c2) The expression vector according to claim 3; (c3) The host cell according to claim 4.

6. Use of the mutant according to claim 1 in the preparation of steviol glycosides.

7. A method for preparing steviol glycosides, characterized in that: include: Preparation of steviol glycosides based on the host cell according to claim 4; The prepared reaction system comprises: 0.1-0.3 g / mL of the host cell according to claim 4, 55-65 mM trisodium citrate, 95-105 mM sodium phosphate buffer with a pH of 7.5-8.5, 0.05-0.15 mM MgCl2, 0.5%-1.5% (v / v) xylene, 350-450 g / L sucrose and 55-65 g / L substrate; The preparation temperature is 38-42°C; The preparation time is 12 to 72 hours.